In the RPV/FTC/TDF arm , isolates from 17/394 subjects ( 4.3 % ) developed nonnucleoside reverse transcriptase inhibitor ( NNRTI ) and/or nucleoside reverse transcriptase inhibitor ( NRTI ) resistance mutations , and 16/17 isolates had both NNRTI and NRTI resistance mutations .